All content is for general information only — not medical advice, not a dosing or usage recommendation, and not a claim of efficacy. Many substances are not approved as medicines or are prescription-only; whether possession and use are legal depends on the law of your country of residence and is your own responsibility. myPeptides does not sell or supply any substances — it is an information and organization tool. For health questions, consult a licensed physician or pharmacist.
Peptide register
Every peptide covered here, with its mechanism class, legal status and WADA status. This is a status register, not a shop: no suppliers, no doses, no efficacy claims.
Class
Legal status
13 of 98
Brenipatide
Dual GIP and GLP-1 receptor agonist in phase 3 for addiction, depression and other non-metabolic uses; not approved anywhere.
MonographCagrilintide
Long-acting amylin analogue in phase 3 development; not approved anywhere.
MonographDulaglutide
Long-acting GLP-1 receptor agonist fusion protein; approved prescription medicine.
MonographEloralintide ELO
Selective amylin receptor agonist in phase 3 development for obesity; not approved in any market.
MonographEnicepatide
Dual GIP and GLP-1 receptor agonist in phase 3 development for obesity and type 2 diabetes; not approved in any market.
MonographExenatide
First licensed GLP-1 receptor agonist; approved prescription medicine since 2005.
Originator products discontinued in the US
MonographLiraglutide
GLP-1 receptor agonist; approved prescription medicine since 2009.
MonographMazdutide
Dual glucagon and GLP-1 receptor agonist; approved as a prescription medicine in China in 2025.
China only
MonographRetatrutide
Triple GIP, GLP-1 and glucagon receptor agonist in phase 3; not approved anywhere.
MonographSemaglutide
GLP-1 receptor agonist; approved prescription medicine in the US and the EU.
MonographSurvodutide
Dual glucagon and GLP-1 receptor agonist in phase 3 development; not approved in any market.
MonographTirzepatide
Dual GIP and GLP-1 receptor agonist; approved prescription medicine.
MonographVK2735
Dual GLP-1 and GIP receptor agonist in phase 3 as a weekly injection, also tested as a daily tablet; not approved in any market.
MonographTake myPeptides with you
Track doses, plans and progress on your phone — end-to-end encrypted.
This article is for informational purposes only and does not replace medical advice. myPeptides gives no dosing recommendations.